Stock Analysts’ updated eps estimates for Friday, August 25th:
AAON (NASDAQ:AAON) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Aaon Inc. is a manufacturer of air-conditioning and heating equipment consisting of rooftop units, chillers, air-handling units, condensing units and coils. Its products serve the new construction and replacement markets. The Company has successfully gained market share through its semi-custom product lines, which offer the customer value, quality, function, serviceability and efficiency. “
Adva Optical Netwo (NASDAQ:ADVOF) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “ADVA Optical Networking SE develops, manufactures and sells optical and Ethernetbased networking solutions. It serves telecommunications service providers, private companies, universities and government agencies. ADVA Optical Networking SE is headquartered in Munich, Germany. “
Abercrombie & Fitch (NYSE:ANF) had its buy rating reaffirmed by analysts at William Blair.
ANTA SPORTS PRODUC HKD0.10 (NASDAQ:ANPDF) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $3.00 price target on the stock. According to Zacks, “ANTA Sports Products Limited designs, develops, manufactures, trades, distributes, and markets sportswear in the People’s Republic of China. The company’s products include footwear, apparel, and accessories for professionals and the general public. ANTA Sports Products Limited is headquartered in Jinjiang City, the People’s Republic of China. “
Anthera Pharmaceuticals (NASDAQ:ANTH) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “
Amerigo Resources LTD (TSE:ARG) had its buy rating reaffirmed by analysts at Fundamental Research. The firm currently has a C$1.00 target price on the stock.
Alliance Resource Partners, L.P. (NASDAQ:ARLP) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “ALLIANCE RESOURCES is a diversified producer and marketer of coal to major U.S. utilities and industrial users. They currently operate mining complexes in Illinois, Indiana, Kentucky and Maryland. Some of their mining complexes are underground and one has both surface and underground mines. They produce a diverse range of steam coals with varying sulfur and heat contents, which enable them to satisfy the broad range of specifications demanded by their customers. “
ArQule (NASDAQ:ARQL) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F-1 pathway, is partnered with Roche. “
Big Lots (NYSE:BIG) was given a $60.00 target price by analysts at Oppenheimer Holdings, Inc.. The firm currently has a buy rating on the stock.
Canadian Imperial Bank of Commerce (TSE:CM) (NYSE:CM) had its market perform rating reaffirmed by analysts at BMO Capital Markets. BMO Capital Markets currently has a C$118.00 target price on the stock.
Canadian Imperial Bank of Commerce (TSE:CM) (NYSE:CM) had its buy rating reissued by analysts at Canaccord Genuity. They currently have a C$116.00 target price on the stock.
Carmanah Technologies Corp (TSE:CMH) was downgraded by analysts at Canaccord Genuity from a buy rating to a hold rating.
Sidoti assumed coverage on shares of Cavco Industries (NASDAQ:CVCO). Sidoti issued a buy rating on the stock.
Home Capital Group (TSE:HCG) was downgraded by analysts at Royal Bank Of Canada from a speculative buy rating to a sector perform rating. Royal Bank Of Canada currently has C$15.00 target price on the stock, up from their previous target price of C$14.00.
New Flyer Industries (TSE:NFI) had its market perform rating reissued by analysts at BMO Capital Markets. BMO Capital Markets currently has a C$57.00 price target on the stock.
